6-methoxy-N-[1-[1-[4-(trifluoromethoxy)benzoyl]piperidin-4-yl]pyrazol-4-yl]-1H-indole-2-carboxamide
C26H24F3N5O4 — CID 171681122
Data last refreshed: (MolForge compound catalog, from PubChem)
About 6-methoxy-N-[1-[1-[4-(trifluoromethoxy)benzoyl]piperidin-4-yl]pyrazol-4-yl]-1H-indole-2-carboxamide
6-methoxy-N-[1-[1-[4-(trifluoromethoxy)benzoyl]piperidin-4-yl]pyrazol-4-yl]-1H-indole-2-carboxamide (PubChem CID 171681122) has the molecular formula C26H24F3N5O4 and a molecular weight of 527.50 g/mol. Its IUPAC name is 6-methoxy-N-[1-[1-[4-(trifluoromethoxy)benzoyl]piperidin-4-yl]pyrazol-4-yl]-1H-indole-2-carboxamide.
Molecular Properties
| Compound Name | 6-methoxy-N-[1-[1-[4-(trifluoromethoxy)benzoyl]piperidin-4-yl]pyrazol-4-yl]-1H-indole-2-carboxamide |
|---|---|
| PubChem CID | 171681122 |
| Molecular Formula | C26H24F3N5O4 |
| Molecular Weight | 527.50 g/mol |
| Exact Mass | 527.18 |
| IUPAC Name | 6-methoxy-N-[1-[1-[4-(trifluoromethoxy)benzoyl]piperidin-4-yl]pyrazol-4-yl]-1H-indole-2-carboxamide |
| SMILES | COc1ccc2cc(C(=O)Nc3cnn(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5)CC4)c3)[nH]c2c1 |
| InChI | InChI=1S/C26H24F3N5O4/c1-37-21-7-4-17-12-23(32-22(17)13-21)24(35)31-18-14-30-34(15-18)19-8-10-33(11-9-19)25(36)16-2-5-20(6-3-16)38-26(27,28)29/h2-7,12-15,19,32H,8-11H2,1H3,(H,31,35) |
| InChIKey | PYZGDJYLLITRMQ-UHFFFAOYSA-N |
| XLogP | 5.00 |
| TPSA | 101.48 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 38 |
| Complexity | — |
Lipinski Rule of Five
2 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 527.50 |
| LogP ≤ 5 | 5.00 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 171681122 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.